VivoSeq
Other

Hyperemesis Gravidarum

8

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Hyperemesis Gravidarum is an early-stage landscape with 8 programs across 4 companies. The most active players are Viatris Specialty LLC, EMD Serono, Novartis. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Terminated1 · 20%

Clinical Trials

Trial Activity

Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
Completed·SState University of New York at Buffalo·Phase 2·NCT02163434·31 enrolled
Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
Completed·—·N/A·NCT04785911·200 enrolled
Hyperemesis Gravidarum Risk Reduction With Metformin
Not yet recruiting·UUniversity of Southern California·Phase 2·NCT07129473·224 enrolled
Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum
Completed·AA.O.U. Città della Salute e della Scienza·Phase 3·NCT01559012·13 enrolled
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
Terminated·NNordsjaellands Hospital·Phase 2·NCT03785691·58 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)